Comparison of Testosterone Levels in Patients With and Without Type 2 Diabetes.

Autor:	Kumari N; Internal Medicine, Dow University of Health Sciences, Karachi, PAK., Khan A; Internal Medicine, Dow University of Health Sciences, Karachi, PAK., Shaikh U; Internal Medicine, Dow University of Health Sciences, Karachi, PAK., Lobes K; Internal Medicine, Liaquat National Hospital and Medical College, Karachi, PAK., Kumar D; Internal Medicine, Jinnah Sindh Medical University, Karachi, PAK., Suman F; Internal Medicine, Peoples University of Medical Health Sciences for Women, Nawabshah, PAK., Bhutto NS; Internal Medicine, Chandka Medical College, Chandka, PAK., Anees F; Internal Medicine, Jinnah Sindh Medical University, Karachi, PAK., Shahid S; Internal Medicine, Jinnah Sindh Medical University, Karachi, PAK., Rizwan A; Family Medicine, Jinnah Post Graduate Medical Center, Karachi, PAK.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2021 Jul 09; Vol. 13 (7), pp. e16288. Date of Electronic Publication: 2021 Jul 09 (Print Publication: 2021).
DOI:	10.7759/cureus.16288
Abstrakt:	Introduction Hypogonadotropic hypogonadism is a common disorder associated with type 2 diabetes. Hypogonadotropic hypogonadism in type 2 diabetic patients requires further assessment to understand the etiology, and the possible consequences, complications, and treatment This study aims to highlight the testosterone level in type 2 diabetes mellitus (DM). Moreover, it further emphasizes the association of testosterone with the duration of DM. Materials and method This case-control survey was conducted from September 2020 to March 2021 in the outpatient department of internal medicine in a tertiary care hospital in Pakistan. The experiment group included 200 diabetic male participants aged between 30 and 69 years. In the control group, 200 participants without DM were enrolled in the study. The venous blood sample was collected via phlebotomy and sent to the laboratory to test for total testosterone level. Results The mean total testosterone level was significantly lower in diabetic patients compared to the non-diabetic patients (8.9 ± 5.1 mmol/L vs. 14.1 ± 7.2 mmol/L; p-value: <0.0001) and the prevalence of androgen deficiency was significantly higher in diabetic patients compared to non-diabetic patients (45.5% vs. 20.5%; p-value: <0.00001). For each age group, the mean total testosterone level was significantly higher in the diabetic group compared to the non-diabetic group. There was a significant decline in mean total testosterone level as the duration of diabetes increased (p-value: 0.01). Conclusion Strong interlink between type 2 DM and low testosterone level has once again highlighted the importance of a broader approach toward men presenting in the diabetic clinic and provided a huge ground for prescribing testosterone replacement therapy in hypogonadal men with DM. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Kumari et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu